Lim JY et al. - In a trial to investigate the efficacy and safety of combination chemotherapy of oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) in biliary tract carcinoma, it was concluded that oxaliplatin in combination with leucovorin and 5-FU is a feasible chemotherapy regimen for pts with recurrent/metastatic biliary tract carcinoma Methods
Pts with unresectable or recurrent biliary tract carcinoma were enrolled, including pretreated and chemotherapy-naive pts
Treatment consisted of intravenous oxaliplatin (100 mg/m2, day 1) followed by leucovorin (100 mg/m2, day 1) and 5-FU (1000 mg/m2, days 1 and 2)
Treatment was repeated every 3 weeks
Efficacy and safety of the treatment were determined
Results
1 complete response and 5 partial responses were noted, with a response rate of 21.5%, according to RECIST criteria
Median time to progression and overall survival was 3.5 months and 10.0 months, respectively
The 1-year survival rate was 17.8%
Grade 3/4 neutropenia and thrombocytopenia were recorded in 18% and 4% of the pts, respectively
See all
